The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
- 1 April 1993
- journal article
- research article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 15 (3), 409-413
- https://doi.org/10.1016/0192-0561(93)90052-z
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- A method for removing interleukin-1- and tumor necrosis factor-inducing substances from bacterial cultures by ultrafiltration with polysulfoneJournal of Immunological Methods, 1989
- Pharmacokinetics of the Antidepressant Rolipram in Healthy VolunteersXenobiotica, 1989
- Measurement of immunoreactive interleukin-1β from human mononuclear cells: Optimization of recovery, intrasubject consistency, and comparison with interleukin-1α and tumor necrosis factorClinical Immunology and Immunopathology, 1988
- Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofyllineBiochemical and Biophysical Research Communications, 1988
- Attenuation of Acute Lung Injury in Septic Guinea Pigs by PentoxifyllineAmerican Review of Respiratory Disease, 1988
- Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In VitroJournal of Leukocyte Biology, 1988
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASEThe Lancet, 1987
- Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitorsNeuropharmacology, 1983